View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
January 15, 2019

BMS/Celgene deal will create haematology powerhouse

Bristol-Myers Squibb has announced its intention to buy Celgene, a deal expected to boost its presence in oncology and haematology.

By GlobalData Healthcare

Although Bristol-Myers Squibb (BMS) was already a leader in oncology, its proposed $74 billion acquisition of Celgene will further position the company as a powerhouse in this therapeutic area, especially within haematology.

GlobalData expects the acquisition will strengthen the company’s position in haematology, with the following marketed products for blood cancers added to its portfolio: Revlimid (lenalidomide), Pomalyst (pomalidomide), Vidaza (azacitidine), Thalomid (thalidomide), Istodax (romidepsin), and Idhifa (enasidenib mesylate).

After the acquisition, 61% of BMS’ oncology portfolio will contain products for blood cancers (including one product for both haematological and solids tumours).

BMS/Celgene’s combined portfolio of approved oncology products for 2019, by solid tumour versus blood cancer

Source: GlobalData, Pharma Intelligence Center [Accessed January 3, 2019]

Notably, Celgene’s portfolio is particularly strong for multiple myeloma, where BMS will acquire an additional three products for this indication, in addition to Empliciti (elotuzumab). Other new additions include products for solid tumours of the lung, urinary tract, gastrointestinal tract, and breast.

BMS/Celgene’s combined portfolio of approved oncology products for 2019, segmented by tumour location

Source: GlobalData, Pharma Intelligence Center [Accessed January 3, 2019] Note: Products may be approved for multiple indications

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology